<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01179776</url>
  </required_header>
  <id_info>
    <org_study_id>THR-PS-02</org_study_id>
    <nct_id>NCT01179776</nct_id>
  </id_info>
  <brief_title>Ilomedin Treatment for Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)</brief_title>
  <official_title>A Single Center, Open, Randomized, Placebo-controlled Study Investigating the Safety of Administration of IlomedinÂ® in Addition to Standard Treatment in Patients Having Undergone Primary Percutaneous Coronary Intervention (PCI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Thrombologic ApS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Lene Holmvang</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Thrombologic ApS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Acute myocardial infarct patients with STEMI (ST-elevation on ECG) whom undergo a primary
      percutaneous cardiac intervention will following the standard treatment , received low dose
      of Ilomedin and to low dose of standard treatment for another 24 hours.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding complications as evaluated by TIMI and GUSTO criteria</measure>
    <time_frame>Feb 2011</time_frame>
    <description>Increased bleeding complications will be evaluated between the active and placebo groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial markers and blood aggregation (measured by TEG and multiplate)</measure>
    <time_frame>Feb 2011</time_frame>
    <description>Endothelial markers will be measured to evaluate the Ilomedin effect on these patients. Blood aggregation and coagulation will be evaluated by using TEG and Multiplate.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Myocardial Infarct</condition>
  <arm_group>
    <arm_group_label>Ilomedin and standard low dose treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilomedin</intervention_name>
    <description>Ilomedin</description>
    <arm_group_label>Ilomedin and standard low dose treatment</arm_group_label>
    <other_name>Iloprost</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>i.v saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilomedin</intervention_name>
    <arm_group_label>Ilomedin and standard low dose treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ilomedin and standard low dose treatment</intervention_name>
    <arm_group_label>Ilomedin and standard low dose treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years

          2. Undergoing primary PCI due to STEMI (TIMI flow I -III before PCI and symptom duration
             &lt; 12 hours)

        6) Following receipt of verbal and written information about the study, the patient must
        provide signed informed consent before any study data is used.

        Exclusion Criteria:

        2) Not able to give informed consent 3) Women with childbearing potential 4) On-going
        concomitant treatment with K-vitamin antagonists (one bolus dose pre-PCI allowed) 5) Known
        congenital or acquired coagulopathy and/or thrombocytopathy s 8) Participation in a
        clinical study and/or another investigational device within the past four weeks prior to
        Day 1 9) Major surgery or trauma within the past 6 weeks prior to Day 1 10) A blood
        coagulation disorder (i.e. international normalized ratio [INR] &gt; 2.0, platelet count &lt;
        100,000/mm3, or hematocrit &lt; 30%) 11) Renal insufficiency (creatinine &gt; 140 mmol/l) 12)
        Major procedure related bleeding (TIMI major criteria); GI or urinary tract bleeding prior
        to inclusion in the trial 13) Known active hepatitis B and/or hepatitis C or HIV 14) Known
        or suspected hypersensitivity to components of the investigational medicinal product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lene Holmvang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lene Holmvang</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2010</study_first_submitted>
  <study_first_submitted_qc>August 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2010</study_first_posted>
  <last_update_submitted>June 1, 2011</last_update_submitted>
  <last_update_submitted_qc>June 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2011</last_update_posted>
  <responsible_party>
    <name_title>Lene Holmvang</name_title>
    <organization>Rigshospitalet</organization>
  </responsible_party>
  <keyword>ST-eleveation</keyword>
  <keyword>Myocardial infarct</keyword>
  <keyword>Percutaneous coronary intervention</keyword>
  <keyword>Myocardial infarct STEMI patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

